

Press Release

Joint Storage and Transportation of Pharmaceuticals in Hokkaido by Astellas, Takeda, Teva Takeda Pharma and Teva Takeda Yakuhin

- Further ensure stable supplies of pharmaceuticals -

Tokyo, February 23, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that Astellas, Takeda Pharmaceutical Company Limited (President and CEO: Christophe Weber, “Takeda”), Teva Takeda Pharma Ltd. (CEO and President Hiroshi Matsumori: “Teva Takeda Pharma”) and Teva Takeda Yakuhin Ltd. (Representative Director: Ichiro Kikushige, “Teva Takeda Yakuhin”) have concluded a memorandum of understanding concerning the establishment of a new structure in Hokkaido for the joint storage and distribution of products of these four companies as well as a jointly-operated logistics center to be located in Sapporo, with the objective of further ensuring stable supplies, qualities and efficient transportation of pharmaceuticals in emergency situations, such as a natural disaster.

In recent years, there have been many natural disasters such as those due to earthquakes, storms and flooding. Maintaining stable supplies of prescription pharmaceuticals at such times is a major issue to be addressed. Another requirement is ensuring quality during storage and transportation considering GDP (Good Distribution Practice). Furthermore, we are now also facing distribution-related issues such as a shortage of truck drivers, maintaining safe operations and reducing CO₂ emissions.

Under the memorandum of understanding, the companies will cooperate with each other in addressing the above issues and environmental changes. Its aims are to create a new structure in Hokkaido for the joint storage (standardization of working and management procedures, etc.) and joint transportation (reduction in number of trucks through standardization of delivery procedures, raising efficiency of loading, etc.) of prescription pharmaceuticals and start operating a joint logistics center by March 2018.

The creation of a stable and efficient logistics platform will enable the companies to fulfill their mission of maintaining stable supplies of pharmaceutical products and ensuring the quality under any conditions. It will also give a sense of security to patients and medical institutions.

###

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473